Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-2843 and Osimertinib in Advanced EGFR Mutant NSCLC
NCT04762199Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRX-2843 in non-small cell lung cancer (NSCLC), sponsored by Emory University. Primary endpoints: Maximum Tolerated Dose up to 3.5 years and Recommended Phase 2 Dose up to 3.5 years. Started Feb 2021; status: recruiting.
02
Drugs
MRX-2843
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04762199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762199.